Telik, Inc. is a biopharmaceutical company focused on the discovery and development of small-molecule biopharmaceuticals for itself and its partners. Three lead programs address large markets in oncology and diabetes. They include TLK286 for chemotherapy-resistant solid tumors, TLK199 for chemotherapy-induced neutropenia, and TLK17411 for Type II diabetes. The company intends to maximize the commercial potential of each of its development programs through corporate partnerships that promote accelerated commercialization of its products.
Share Information
Market Value, $K:
6,380
Shares Outstanding, K:
4,560
% Held by Insiders:
4.19%
% Institutional Shareholders:
3.71%
Last Quarter Sales, $M:
N/C
Last Quarter Net Income, $M:
-1.94
Last Quarter EPS:
-0.46
P/E Ratio:
0.00
Annual EPS, $:
-3.01
Most Recent Earnings, $:
Annual Dividend Rate, $:
0
Most Recent Dividend:
Annual Dividend Yield, %:
0%
Most Recent Split:
1-30 on 04/02/12
Fundamental information provided by Zacks Investment Research, Inc.
Zacks does not represent, warrant,
or guarantee completeness, accuracy or timeliness of its data, and shall have no liability of any kind whatsoever
to any party on account of any incompleteness of, inaccuracies in or untimeliness of the Zacks content provided
hereunder, or for any delay in reporting such data. Zacks expressly disclaims all warranties of fitness of the
Zacks content or computations and analyses thereof for a particular purpose or use.
